# A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

> **NCT00546247** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 26 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Epofolate

## Key facts

- **NCT ID:** NCT00546247
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546247, "A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00546247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*